PHARMAC update on proposed changes to anti-VEGF treatments for ophthalmic use

28 October 2016

On September 25, 2016, New Zealand’s Pharmaceutical Management Agency PHARMAC consulted on a proposal to list Novartis’ (NOVN: VX) Lucentis (ranibizumab) and Bayer’s (BAYN: DE) Eylea (aflibercept) in Section H of the Pharmaceutical Schedule from November 1, 2016 for the treatment of wet age-related macular degeneration (wet AMD).

This proposal arose following a Request for Proposals (RFP)for the supply of anti-endothelial growth factor (anti-VEGF) agents for ophthalmic use (primarily wet aged macular degeneration (wet AMD)) issued on May 5, 2016.

PHARMAC received detailed consultation feedback on this proposal from a number of interested parties which we are taking some more time to carefully consider. This means a decision on the proposal as consulted upon will be delayed and therefore, for the avoidance of doubt, the proposed changes to listings will not occur on November 1, 2016.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK